EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats

Ewa Galaj, Saadet Inan, Guo-Hua Bi, Sonita Wiah, George Adamson, Allen B Reitz, Zheng-Xiong Xi iD, Scott M Rawls

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Ewa Galaj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Psychological and Brain Sciences, Colgate University, Hamilton, New York, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Opioid-Related Disorders, Drug-Seeking Behavior. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, Intramural Research Program, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Riluzole, approved for amyotrophic lateral sclerosis (ALS), has a glutamate‐modulating profile favourable for mitigating opioid addiction. It reduces neuronal glutamate release and enhances glutamate reuptake, offering advantages over agents that only increase glutamate reuptake. However, riluzole has pharmacokinetic liabilities that limit repurposing. To overcome these limitations, we designed and prepared the prodrug troriluzole (TRLZ), which retains the mechanistic profile of riluzole but with optimized metabolic and pharmacokinetic properties (e.g., higher oral bioavailability and less pharmacokinetic variability). As dysregulation of glutamate systems during opioid exposure contributes to adverse opioid effects, we tested the hypothesis that TRLZ would inhibit several opioid‐derived adverse effects in rats. Experimental Approach In male Long–Evans and Sprague–Dawley rats, effects of TRLZ on oxycodone self‐administration were investigated under fixed‐ratio and progressive‐ratio reinforcement schedules. Effects of TRLZ on food self‐administration were also investigated. TRLZ effects on cue‐induced reinstatement of oxycodone seeking, and on morphine‐induced physical dependence, antinociceptive tolerance and respiratory depression were also investigated. TRLZ was administered intraperitoneally. Key Results TRLZ dose‐dependently reduced oxycodone self‐administration, reinforcing efficacy and cue‐induced reinstatement of oxycodone seeking without affecting inactive lever responding. TRLZ, at high doses, also inhibited food self‐administration. TRLZ reduced naloxone‐precipitated withdrawal signs in morphine‐dependent rats and antinociceptive tolerance during repeated morphine exposure. TRLZ also attenuated morphine‐induced respiratory depression. Conclusions and Implications TRLZ, already in clinical trials for cerebellar ataxia, also reduced opioid taking and seeking as well as opioid‐derived adverse effects in rats, supporting further study in treating opioid use disorders and pain management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidOpioid-Related DisordersDrug-Seeking BehaviorAnimalsMaleRats, Sprague-DawleyDrug ToleranceRatsRats, Long-EvansSelf AdministrationOxycodoneMorphineBehavior, AnimalReinforcement, PsychologyRiluzole

Stichwörter der Autor:innen

GLT‐1glutamatemorphineopioidoxycodonerelapsetolerancetroriluzole

Substanzen

Analgesics, OpioidOxycodoneMorphineRiluzole

Autor:innen und Institutionen

  • Psychological and Brain Sciences, Colgate University, Hamilton, New York, USA.
  • Addiction Biology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland, USA.
  • Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
  • Fox Chase Therapeutics Discovery Incorporated, Doylestown, Pennsylvania, USA.
  • Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Zheng-Xiong Xi

Förderung

  • NIDA NIH HHS
  • Intramural Research Program
  • NIH HHS
  • Intramural NIH HHS
  • NIAAA NIH HHS

Zitieren

APA

Galaj, E., Inan, S., Bi, G. H., Wiah, S., Adamson, G., Reitz, A. B., Xi, Z. X., & Rawls, S. M. (2026). Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats. British Journal of Pharmacology. https://doi.org/10.1111/bph.70206

Vancouver

Galaj E, Inan S, Bi GH, Wiah S, Adamson G, Reitz AB, et al. Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats. British Journal of Pharmacology. 2026. doi:10.1111/bph.70206

BibTeX
@article{Galaj2026,
  author = {Galaj, Ewa and Inan, Saadet and Bi, Guo-Hua and Wiah, Sonita and Adamson, George and Reitz, Allen B and Xi, Zheng-Xiong and Rawls, Scott M},
  title = {Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70206}
}
Kostenlos starten →